Earlier this month, Aastrom Biosciences Inc.'s president and CEO, Tim Mayleben, told BioWorld Today that his firm likely would complete a financing this quarter to help support the recently launched Phase III critical limb ischemia (CLI) trial. (See BioWorld Today, March 2, 2012.)